drugset / Trial / NCT00044356

Phase II Trial of Allovectin-7® for Metastatic Melanoma

NCT00044356

Phase 2 Completed 133 enrolled Vical
Parallel-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.

Timeline

Start
2001-02
Primary completion
2004-08
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Allovectin-7® Other / unclassified Other

Indications